Abstract
Objective Determine the seroprevalence and 3 month temporal change of SARS-COV-2 in the US and Puerto Rico in an asymptomatic well population.
Results The prevalence of SARS-CoV-2 in the asymptomatic population has doubled during the May to September time period, going from 3.0% to 6.6%. Positive serology to SARS-COV-2 was similar in males and females but varies by age. The greatest increase was in the youngest population. Based on the September prevalence it is estimated that there are 11.1 million (bootstrap 95% CI: 10.8 – 11.5 million) asymptomatic SARS-CoV-2 infections in the US, which is 1.95 times the cumulative number of cases in the US reported to the CDC as of September 1, 2020.
Conclusions The number of new SARS-COV-2 cases more than doubled in this 3 months period. The seroprevalence by age group is high in the youngest (<20, 7.8%) and low in the oldest (> 70, 2.0%). Over the three month study period the rate of increase in prevalence for SARS-COV-2 serology varies by state with a range from 0.84 (State of New York) to more than 12 (Tennessee). This study identifies states were public health mitigation has blunted the spread and also areas where additional levels of intensified public education, surveillance and targeted intervention may be warranted.
Objective Determine the rate of change in prevalence of SARS-COV-2 antibody in a self-reported asymptomatic well population over a three month period.
Method Between 12 May and 25 September we examined SARS-COV-2 antibody results on 113,369 consecutive life insurance applicants who were having blood drawn for the purpose of underwriting mortality risk.
Results In May the seroprevalence of SARS-CoV-2 was 3.0%(547/18,441), 3.1%(981/31,822) in June and 6.6%(4180/63,103) in September. Positive serology to SARS-COV-2 was similar in males and females but varies by age. Geographical distribution revealed a very high level of various between states. Using 2019 US Census state population data to adjust state specific rates of positivity, it is estimated that the September level of seropositivity would correspond to 11.1 million asymptomatic SARS-CoV-2 infections in the US, which is roughly 2 times the cumulative number of cases in the US reported to the CDC as of September 1, 2020.
Conclusions The prevalence of positive SARS-COV-2 serology increased more than 2 fold during the three month period from May to September 2020 going from 3.0% to 6.6%. During this period state specific rates of increase in prevalence vary wildly from 0.8(New York) to more than 12 fold (Tennessee). The estimated number of total SARS-CoV-2 infections based on positive serology is substantially higher than the total number of cases reported to the CDC. This study identifies states were public health mitigation has blunted the spread and also areas where additional levels of intensified public education, surveillance and targeted intervention may be warranted.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not a clinical trial
Funding Statement
Institutional Self-funded
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Western IRB reviewed the study under the Common Rule and applicable guidance and determined it is exempt under 45 CFR 46.104(d)(4) using de-identified study samples for epidemiologic investigation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available to non-profit organizations.
